Effects of Zoledronic Acid on Bone Remodeling in Beagle Dogs
Author Information
Author(s): Allen Matthew R, Kubek Daniel J, Burr David B
Primary Institution: Indiana University School of Medicine
Hypothesis
Monthly intravenous zoledronic acid would significantly suppress intracortical remodeling at all skeletal sites compared with both vehicle- and alendronate-treated animals.
Conclusion
Monthly intravenous zoledronic acid dosing results in nearly complete suppression of bone remodeling in the mandible and significant suppression in the rib and tibia.
Supporting Evidence
- ZOL treatment resulted in a 95% reduction in bone remodeling after 3 months.
- After 6 months, ZOL treatment led to a 99% reduction in bone remodeling in the mandible.
- ZOL significantly suppressed remodeling in the rib cortex by 83% after 3 months and 85% after 6 months.
- ALN did not significantly suppress intracortical bone formation rate compared to VEH.
Takeaway
This study shows that a medicine called zoledronic acid can stop bones from changing too much in dogs, especially in their jaws.
Methodology
Sixty skeletally mature female beagle dogs were treated with either monthly intravenous infusions of zoledronic acid or daily oral alendronate, and their bone remodeling was assessed after 3 and 6 months.
Limitations
The study was conducted on a specific animal model, which may not fully represent human responses.
Participant Demographics
Skeletally mature female beagle dogs, aged 1 to 2 years.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website